Prognostic significance of preoperative and postoperative CK19 and CEA mRNA levels in peripheral blood of patients with gastric cardia cancer. 2017

Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
Yu-Feng Qiao, Chuan-Gui Chen, Jie Yue, Ming-Quan Ma, Zhao Ma, Zhen-Tao Yu, Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin 300060, China.

OBJECTIVE To evaluate the clinical and prognostic significance of preoperative and postoperative cytokeratin 19 (CK19) and carcinoembryonic antigen (CEA) mRNA levels in peripheral blood of patients with gastric cardia cancer (GCC). METHODS We detected the preoperative and postoperative mRNA levels of CK19 and CEA in peripheral blood of 129 GCC patients by using reverse transcription-polymerase chain reaction and evaluated their clinical and prognostic significance by univariate Kaplan-Meier survival analysis and multivariate Cox proportional hazard analysis. A new prognostic model which stratified patients into three different risk groups was established based on the independent prognostic factors. RESULTS Elevated preoperative and postoperative CK19 and CEA mRNA levels in peripheral blood of GCC patients were associated with lymph node metastasis. Univariate analysis showed that tumor size, histological grade, depth of tumor invasion, lymph node metastasis, preoperative CK19 mRNA, and preoperative and postoperative CEA mRNA levels were correlated with the prognosis of GCC patients. The multivariate analysis showed that lymph node status (P = 0.018), preoperative CK19 (P = 0.035) and CEA (P = 0.011) mRNA levels were independent prognostic factors for overall survival (OS). The 5-year OS rates for the low-, intermediate-, and high-risk groups were 48.3%, 22.6%, and 4.6%, respectively (P < 0.001). CONCLUSIONS Elevated preoperative CK19 and CEA mRNA levels may be regarded as promising biomarkers for predicting lymph node metastasis and poor prognosis in patients with GCC. This new prognostic model may help us identify the subpopulations of GCC patients with the highest risk.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D002299 Cardia That part of the STOMACH close to the opening from ESOPHAGUS into the stomach (cardiac orifice), the ESOPHAGOGASTRIC JUNCTION. The cardia is so named because of its closeness to the HEART. Cardia is characterized by the lack of acid-forming cells (GASTRIC PARIETAL CELLS). Cardias
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
September 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
July 2006, Journal of surgical oncology,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
October 2009, Annals of surgical oncology,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
January 2019, Cancer management and research,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
December 2001, Cancer research and treatment,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
August 2008, Zhonghua yi xue za zhi,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
December 2006, The Kaohsiung journal of medical sciences,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
June 2006, Journal of Zhejiang University. Science. B,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
December 2010, Experimental oncology,
Yu-Feng Qiao, and Chuan-Gui Chen, and Jie Yue, and Ming-Quan Ma, and Zhao Ma, and Zhen-Tao Yu
November 1994, Pancreas,
Copied contents to your clipboard!